Medicine and Dentistry
Analysis
9%
Angiogenesis Inhibitor
9%
Antibody-Drug Conjugate
9%
Avelumab
9%
Biological Marker
100%
Carcinoma in Situ
9%
Chemotherapy Agent
18%
Combination Therapy
9%
Cystectomy
9%
Development
9%
Diseases
18%
Evaluation Study
9%
Inpatient
18%
Muscle
27%
Nivolumab
9%
Non Muscle Invasive Bladder Cancer
18%
Overall Survival
9%
Patient
45%
Patient Care
9%
Patient Selection
9%
Pembrolizumab
9%
Progression Free Survival
9%
Radiation Therapy
9%
Radical Surgery
9%
Recurrence Free Survival
9%
Recurrent Disease
9%
Targeted Therapy
9%
Therapeutic Procedure
36%
Toxicity
27%
Transitional Cell Carcinoma
100%
Pharmacology, Toxicology and Pharmaceutical Science
Angiogenesis Inhibitor
9%
Antibody Drug Conjugate
9%
Bacilli
9%
Biological Marker
100%
Carcinoma in Situ
9%
Chemotherapy
54%
Diseases
18%
Nivolumab
9%
Non Muscle Invasive Bladder Cancer
18%
Overall Survival
9%
Pembrolizumab
9%
Progression Free Survival
9%
Recurrence Free Survival
9%
Recurrent Disease
9%
Toxicity
27%
Transitional Cell Carcinoma
100%